MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial
MSD’s sac-TMT is being developed in collaboration with Kelun-Biotech in a range of cancer indications.
Therapy Area
ECO 2026: targeting organs, not just weight, defines next wave of obesity therapy
New findings link common pesticide to early-onset colorectal cancer
Hantavirus outbreak demonstrates need for more antiviral agents
Fractyl Health’s GLP-1 gene therapy trial given green light
Hantavirus cruise ship outbreak: case numbers rise to ten
Moderna’s mRNA flu vaccine more effective than current SOC
Viridian Therapeutics’ stock up 35% after Phase III TED data release
